In a first study, Lynch et al. sequenced the codon region of EGFR in nine lung adenocarcinoma patients who had a major or partial response to gefitinib (a first-generation EGFR TKI), and identified somatic mutations in the EGFR kinase domain [7]. The gene discussed is EGFR; the disease is lung adenocarcinoma.